Santeri A Pakola, Katriina J Peltola, James H A Clubb, Elise Jirovec, Lyna Haybout, Tatiana V Kudling, Tuomo Alanko, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Jorma Sormunen, Jukka Kemppainen, Annabrita Hemmes, Teijo Pellinen, Mirte van der Heijden, Dafne C A Quixabeira, Claudia Kistler, Suvi Sorsa, Riikka Havunen, Joao M Santos, Victor Cervera-Carrascon, Akseli E Hemminki
PURPOSE: TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus armed with tumor necrosis factor alpha and interleukin-2, designed to induce T-cell infiltration and cytotoxicity in solid tumors. PATIENTS AND METHODS: TUNIMO (NCT04695327) was a single-arm, multicenter phase I dose escalation trial designed to assess safety of TILT-123 in advanced solid cancers refractory to standard therapy. Patients received intravenous and intratumoral TILT-123. The primary endpoint was safety by adverse events (AEs), laboratory values, vital signs, and electrocardiograms...
March 28, 2024: Clinical Cancer Research